Neoadjuvant camrelizumab plus carboplatin/paclitaxel for advanced endometrioid endometrial cancer

A Single-arm, Multicenter Phase II Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer in Clinical Efficacy

This study will test whether adding the PD-1 inhibitor camrelizumab to neoadjuvant carboplatin and paclitaxel helps people with stage III–IV endometrioid endometrial cancer become operable and have better outcomes.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (estimated)
• Ages: 18 Years to 75 Years
• Sex: Female
• Sponsor: Women's Hospital School Of Medicine Zhejiang University (Academic / other)
• Drugs / interventions: immunotherapy, prednisone, camrelizumab, chemotherapy
• Locations: 1 site (Hangzhou, Zhejiang)
• Trial ID: NCT06561308 on ClinicalTrials.gov

What this trial studies

This is a domestic multicenter, prospective phase II single-arm trial enrolling patients with FIGO stage III–IV endometrioid endometrial cancer. Participants receive neoadjuvant camrelizumab combined with carboplatin and paclitaxel, followed by surgery when resection becomes feasible. Primary outcomes include remission rate, surgical resection rate, and surgical complications, and secondary outcomes include survival and safety. The trial will also profile tumor immune markers and molecular subtypes before and after therapy to identify biomarkers predicting response.

Who should consider this trial

Good fit: Ideal candidates are adults 18–75 years old with pathologically confirmed endometrioid endometrial cancer staged III (non-operable resectable) or IV, ECOG 0–1, adequate laboratory and organ function, and willingness to undergo neoadjuvant therapy, surgery, follow-up, and provide informed consent.

Not a fit: Patients with non-endometrioid histology, poor performance status, uncontrolled comorbidities, active autoimmune disease, or inadequate organ function are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the combination could increase the chance that advanced tumors become operable and may improve survival.

How similar studies have performed: PD-1 inhibitors have shown meaningful activity in endometrial cancer—especially dMMR/MSI‑high tumors—and chemo–immunotherapy combos have shown promise in other cancers, but neoadjuvant use in advanced endometrial cancer is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Endometrial cancer initially diagnosed as stage III non-operable resectable, stage IV (FIGO, 2009 criteria) after imaging evaluation
2. Pathologically confirmed endometrial cancer that looks like endometrial carcinoma
3. Patient age ≥18 years and ≤75 years old
4. ECOG status score of 0-1
5. tolerate surgery and radiotherapy
6. Laboratory tests: WBC ≥3.5×109/L, NEU ≥1.5×109/L, PLT ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L.

   ×109/L, serum bilirubin ≤1.5 times the high limit of normal value, transaminase ≤1.5 times the high limit of normal value, BUN ≤1.5 times the high limit of normal value.

   1.5 times of the high limit of normal value, BUN, Cr≤normal value;
7. Able to follow up and good compliance;
8. Able to sign the informed consent form, including compliance with the requirements and restrictions listed in the informed consent form and the program.

Exclusion Criteria:

1. Subjects with an active, known, or suspected autoimmune disease, or a history of an autoimmune disease, except for: vitiligo, alopecia areata, Graves' disease, psoriasis, or eczema that has not required systemic therapy within the last 2 years, hypothyroidism that is asymptomatic or requires only stable doses of hormone replacement therapy (due to autoimmune thyroiditis), type 1 diabetes that requires only stable doses of insulin replacement therapy, asthma that subsides completely in childhood and does not require intervention in adulthood, or diseases that do not recur in the absence of external triggers;
2. Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or any treatment directed against immune co-stimulators (e.g., antibodies directed against ICOS, CD40, CD137, GITR, OX40 targets, etc.) that target any mechanism of immune action against tumors;
3. Known hypersensitivity to any component and/or any excipient of the trial regimen;
4. Immunosuppressive drugs or systemic corticosteroids for immunosuppression (\>10 mg/day of prednisone or other equivalent) within 2 weeks prior to trial dosing; topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are permitted;
5. Received herbs with antitumor effects or drugs with immunomodulatory effects (e.g., thymidine, interferon, interleukin-2) within 2 weeks prior to the trial;
6. Active systemic infection requiring systemic treatment;
7. Serious infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;
8. Patients with untreated chronic hepatitis B, or HBV carriers with chronic hepatitis B virus (HBV) DNA greater than 1,000 IU/mL, or patients with active hepatitis C. Inactive HBsAg carriers, treated hepatitis B patients with stable disease (HBV DNA \< 1000 IU/mL), and cured hepatitis C patients will be eligible for enrollment. HCV antibody-positive subjects will be eligible for the study only if they have a negative HCV RNA test;
9. Known active tuberculosis (TB), patients with suspected active TB should undergo chest X-ray and sputum examination in conjunction with clinical signs and symptoms for exclusion;
10. Immunodeficiency or human immunodeficiency virus (HIV antibody positive);
11. Subjects with active inflammatory bowel disease or a history of such disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea). Subjects who are unable to swallow or who have malabsorption syndrome, uncontrolled nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely interfere with drug intake and absorption;
12. Known interstitial lung disease that is symptomatic or may interfere with detection or treatment of immune-associated pneumonia;
13. Treatment with a live or attenuated vaccine administered within 4 weeks prior to the first trial dose, inactivated seasonal influenza virus vaccine is permitted;
14. Patients who have received a prior allogeneic bone marrow transplant or solid organ transplant;
15. History of primary malignant tumor within the last 5 years;
16. Subjects who have undergone major surgery (e.g., open abdomen, open chest, organ resection, etc.) and severe trauma within 28 days prior to the first dose of implantable infusion devices are permitted;
17. Subjects with a history of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula;
18. Uncontrolled other co-morbidities, symptoms, or medical history, including: (1) Persons with one of the following cardiovascular diseases or cardiovascular risk factors: myocardial infarction, unstable angina pectoris, pulmonary embolism, acute/continuous myocardial ischemia, cerebral vascular accident, transient ischemic attack, theor other clinically significant/required drug intervention arterial or venous thrombosis, embolism or cerebral ischemic events; symptoms of congestive heart failure (NYHA class III or higher) within 6 months (ii) clinically significant bleeding symptoms or a history of significant bleeding characteristics, such as gastrointestinal bleeding, gastric ulcer bleeding, or vasculitis, within 1 month prior to the first dose; (iii) clinically active hemoptysis, active diverticulitis, abdominal abscess, and gastrointestinal obstruction; (iv) uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; (v) abnormalities of hepatic or renal development, or a history of surgery;
19. Female patients who are pregnant or breastfeeding; women of childbearing age who refuse to accept contraceptive measures during neoadjuvant immunotherapy;
20. Concurrent participation in other interventional clinical trials; participation in observational and non-interventional clinical trials is permitted;
21. Any condition that, in the opinion of the Investigator, may result in risk in the receipt of the study drug or that would interfere with the evaluation of the safety of the study drug or the interpretation of the study results. In the judgment of the Investigator, it is unlikely that Patients who, in the judgment of the Investigator, are less likely to comply with the study steps, restrictions, and requirements shall not be permitted to participate in this study.

Where this trial is running

Hangzhou, Zhejiang

• Women's hospital school of medicine zhejiang university — Hangzhou, Zhejiang, China (Recruiting)

Study contacts

• Principal investigator: Hui Wang, PHD — Women's Hospital School Of Medicine Zhejiang University
• Study coordinator: Yang Li, PHD

Conditions Endometrioid Endometrial Cancer; Neoadjuvant chemotherapy; PD-1 inhibitor